Brand Intelligence Graph
Company Overview
About Stipple Bio
Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andreessen Horowitz Bio+Health, and Nextech, with additional participation from GV and Emerson Collective — a top-tier syndicate that signals strong scientific conviction in the platform.
Business Model & Competitive Advantage
The company's "Pointillist" platform identifies tumor-specific cell surface epitopes for antibody-drug conjugates (ADCs), taking a differentiated approach in one of oncology's most competitive and capital-intensive therapeutic categories. While the ADC field has become crowded following the success of drugs like Enhertu, Stipple's approach focuses on discovering novel epitopes that existing ADCs cannot access, creating a potential source of first-in-class assets.
Competitive Landscape 2025–2026
Stipple's lead asset, STP-100, is targeted to enter clinical studies in 2027. The company's oversubscribed round in the current biotech funding environment is a strong signal of scientific credibility. With backing from investors who collectively represent hundreds of oncology investments, Stipple enters the clinic with a well-resourced balance sheet and strategic relationships across the oncology ecosystem.
Key Differentiators
Strong Challenger
Stipple Bio is an established challenger with significant market presence and competitive offerings in BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Caris Life Sciences
Caris Life Sciences is a precision oncology company founded in 1998 and headquartered in Irving, Texas, that provides comprehensive molecular profiling tests used by oncologists to select personalized
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Compare Stipple Bio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Stipple Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Stipple Bio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Stipple Bio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →